云顶新耀-B(01952.HK)治疗转移性乳腺癌新药亚洲三期临床试验完成首例患者给药
云顶新耀-B(01952.HK)公布,抗体药物偶联物Trodelvy(sacituzumab govitecan)用於治疗转移性乳腺癌的亚洲三期临床试验完成首例患者给药,该研究用於评估该药在治疗激素受体阳性(HR+)/人表皮生长因数受体2阴性(HER2-)转移性乳腺癌(mBC)与医生选择的治疗方案(TPC)的对比。
EVER-132-002是一项亚洲3期研究,旨在评估和比较sacituzumab govitecan与医生选择的治疗方案对接受过至少两种但不超过四种系统性化疗的HR+/HER2-转移性乳腺癌亚洲患者的安全性和有效性。试验将在中国大陆、中国台湾和韩国招募330名HR+/HER2-的转移性乳腺癌患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.